Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.
Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW. Self WH, et al. Among authors: fontaine mj. Res Sq [Preprint]. 2021 Mar 2:rs.3.rs-227796. doi: 10.21203/rs.3.rs-227796/v1. Res Sq. 2021. PMID: 33688640 Free PMC article. Updated. Preprint.
Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.
Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR Jr, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW; Passive Immunity Trial for Our Nation (PassITON) Investigators. Self WH, et al. Among authors: fontaine mj. Trials. 2021 Mar 20;22(1):221. doi: 10.1186/s13063-021-05171-2. Trials. 2021. PMID: 33743799 Free PMC article.
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components.
Wheeler AP, Snyder EL, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Liu K, Bentow S, Varrone J, Benjamin RJ, Corash LM. Wheeler AP, et al. Blood Adv. 2024 May 14;8(9):2290-2299. doi: 10.1182/bloodadvances.2023012425. Blood Adv. 2024. PMID: 38447116 Free PMC article.
The BEST criteria improve sensitivity for detecting positive cultures in residual blood components cultured in suspected septic transfusion reactions.
Shih AW, Cohn CS, Delaney M, Fontaine MJ, Martin I, Dunbar NM; SCARED Study Investigators on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Shih AW, et al. Among authors: fontaine mj. Transfusion. 2019 Jul;59(7):2292-2300. doi: 10.1111/trf.15317. Epub 2019 Apr 23. Transfusion. 2019. PMID: 31013368 Clinical Trial.
Limitations of current practices in detection of bacterially contaminated blood products associated with suspected septic transfusion reactions.
Martin IW, Cohn CS, Delaney M, Fontaine MJ, Shih AW, Dunbar NM; SCARED Study Investigators on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Martin IW, et al. Among authors: fontaine mj. Transfusion. 2021 Aug;61(8):2414-2420. doi: 10.1111/trf.16545. Epub 2021 Jun 28. Transfusion. 2021. PMID: 34181247
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components.
Snyder EL, Wheeler AP, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella P, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Lin JS, Liu K, Bentow S, Peng HL, Varrone J, Benjamin RJ, Corash LM. Snyder EL, et al. Transfusion. 2022 Jul;62(7):1365-1376. doi: 10.1111/trf.16987. Epub 2022 Jun 24. Transfusion. 2022. PMID: 35748490 Free PMC article.
Transfusion of blood components containing ABO-incompatible plasma does not lead to higher mortality in civilian trauma patients.
Seheult JN, Dunbar NM, Hess JR, Tuott EE, Bahmanyar M, Campbell J, Fontaine M, Khan J, Ko A, Mi J, Murphy MF, Nykoluk T, Poisson J, Raval JS, Shih A, Sperry JL, Staves J, Wong M, Yan MTS, Ziman A, Yazer MH; Biomedical Excellence for Safer Transfusion (BEST) collaborative. Seheult JN, et al. Transfusion. 2020 Nov;60(11):2517-2528. doi: 10.1111/trf.16008. Epub 2020 Sep 9. Transfusion. 2020. PMID: 32901965
90 results